Navigation Links
Hemostemix Announces Formation of Scientific Advisory Board
Date:6/10/2013

Toronto, Ontario (PRWEB) June 10, 2013

The Hemostemix Group of Companies announced today the formation of its Scientific Advisory Board (the “Board”) and the addition of its first three members.

The Hemostemix Group is comprised of Hemostemix Ltd. (Hemostemix), a company incorporated in Israel with an operating research, development and manufacturing facility in Ness Ziona, Kwalata Trading Ltd. (“Kwalata”), registered in Cyprus, and the parent company Theravitae, Inc. (“TVI”) based in Toronto, Ontario, Canada (collectively the “Hemostemix Group” or “Group”).

The first three members of the Board to be announced are:

Dr. Heinz Redl

Heinz Redl, Ph.D. is the Chair-elect of the European Chapter of the Tissue Engineering and Regenerative Medicine International Society, head of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology and Associate Professor at the Vienna University of Technology. He is coordinator of the Austrian Cluster for Tissue Regeneration (together with the Medical University Vienna) with 5 branches – bone, cartilage, peripheral nerve, soft tissue (wound healing) and imaging - and also the CEO of the non-profit Trauma Care Consult.

Dr. Norman Wong

Norman C.W. Wong, M.D., F.R.C.P.(C) is a Fellow of The Royal College of Physicians of Canada and is currently a Professor in the Departments of Medicine, Biochemistry and Molecular Biology in the Faculty of Medicine at the University of Calgary. His previous roles include Associate VP Research and International, assistant Dean of research for the faculty of Medicine and as well as Director of the Libin Gene Therapy Unit. He has acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories.

Dr. Mark Zucker

Mark Jay Zucker, M.D., J.D., F.A.C.C., F.A.C.P. is Director of the Harvey and Georgina Weinstein National Heart Transplant Center at Newark Beth Israel Medical Center and Clinical Professor of Medicine at the University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, N.J. Dr. Zucker graduated from Northwestern University with his medical degree and from Loyola University with a law degree. Prior to his current appointments, Dr. Zucker has served in faculty positions at Mount Sinai School of Medicine in New York and Loyola University Medical School in Illinois. He currently is Advisory Board Vice-Chair and on the Board of Directors for the New Jersey Organ & Tissue Sharing Network. He has been involved with heart and lung transplantation and mechanical circulatory support for over 25 years and has been a principal or co-investigator on more than 40 trials including trials of cell-based therapies such as the BioHeart myoblast trial and the ongoing Baxter RENEW trial.

“We are committed to having a world-class Scientific Advisory Board we can draw expertise from as we move forward with our strategy and particularly with the phase 2 trial of our cell therapy product for patients with critical limb ischemia recently cleared to proceed by Health Canada,” stated Hemostemix Group President Dr. Valentin Fulga. “Each of the three members announced today has followed our company and its technology for some time and we are very pleased they have agreed to join our SAB,” Fulga concluded.

Further announcements about additions to the Hemostemix Group’s Scientific Advisory Board are expected to be made in the near future.

About Hemostemix Ltd

Hemostemix Ltd is a company incorporated in Israel with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona. Hemostemix and Kwalata Trading Ltd (“Kwalata”), registered in Cyprus, are wholly-owned subsidiaries of Canadian-based parent company, Theravitae Inc (“TVI”) (collectively, the “Hemostemix Group”).    On 14 May 2013, TVI announced a letter of intent signed with Technical Ventures RX Corp (TSX-V:TIK.P) (“Technical”) regarding a proposed Qualifying Transaction in which Technical would acquire TVI and its subsidiaries in a share transaction. For more information see http://www.hemostemix.com.

Read the full story at http://www.prweb.com/releases/2013Hemostemix/SAB/prweb10807580.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. The Hemostemix Group of Companies Provides Corporate Strategy Update
2. Hemostemix Announces US Patent Allowance
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Spherix Announces Third Quarter Financial Results
11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... ... ... Algenist continues to disrupt the skincare industry with today’s debut of GENIUS Liquid ... the key structural element skin needs to maintain its youthful appearance and Algenist is ... First to market with proprietary collagen water active , Active ...
(Date:8/10/2017)... ... August 09, 2017 , ... Teachers from three Philadelphia middle ... 14th through the 16th, the University City Science Center will kick off the ... provides Philadelphia-based middle school educators an opportunity for professional development related to STEM ...
(Date:8/10/2017)... ... August 09, 2017 , ... Okyanos Center for Regenerative Medicine has announced its ... Hotel in Freeport, Grand Bahama on September 27, 2017. This daytime event is free ... from the Ministry of Health’s National Stem Cell Ethics Committee (NSCEC) and regulations laid ...
(Date:8/10/2017)... USA, and CARDIFF, UK (PRWEB) , ... August ... ... and photonics, has announced an agreement establishing Kinokuniya Company Ltd. as its exclusive ... SPIE as the exclusive sales representative for the SPIE Digital Library in Japan. ...
Breaking Biology Technology:
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
Breaking Biology News(10 mins):